Clinical Trials
10 trialsNCT05827614 2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1 Active not recruiting
NCT01257594 2023-05-25
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Columbia University
Phase 1 Completed
NCT00509431 2020-07-31
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT01103375 2018-08-01
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Wake Forest University Health Sciences
Phase 1 Terminated
NCT00397384 2015-09-30
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00609999 2014-07-16
Ph I Dasatinib + Erlotinib in Recurrent MG
Duke University
Phase 1 Completed
NCT00077454 2013-06-05
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00030498 2013-01-16
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT00227032 2012-03-06
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT00603356 2011-09-27
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Astellas Pharma Inc
Phase 1 Completed